Nilotinib (hydrochloride)

Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia[1][2][3].

Product Specifications

CAS Number

[923288-95-3]

Product Name Alternative

AMN107 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H315-H319-H360

Target

Autophagy; Bcr-Abl

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nilotinib-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3.[H]Cl

Molecular Formula

C28H23ClF3N7O

Molecular Weight

565.98

Precautions

P264-P280-P302+P352-P305+P351+P338-P362+P364-P405-P501

References & Citations

[1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109 (5) :2112-20.|[2] Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9 (9) :e107613.|[3]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.